PRISM BioLab Co

PRISM BioLab Co OCF Growth YoY

The Year-over-Year Operating Cash Flow Growth of PRISM BioLab Co (206A.T) as of Nov 10, 2026 is -1,077.97 %. In the previous year, Year-over-Year Operating Cash Flow Growth was 129.22 % — a change of -934.20% (lower).

OCF Growth YoY

-1,077.97 %

YoY

-934.20%

Last updated:

Year-over-Year Operating Cash Flow Growth of PRISM BioLab Co is 2025 -1,077.97 % . Year-over-Year Operating Cash Flow Growth of PRISM BioLab Co was 2024 129.22 % . It decreases by -934.20% lower compared to the previous year.

The PRISM BioLab Co OCF Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Growth YoY
Date
OCF Growth YoY
Jan 1, 2023
-599.03 JPY
Jan 1, 2024
129.22 JPY
Jan 1, 2025
-1,077.97 JPY
The PRISM BioLab Co OCF Growth YoY history
YEAROCF Growth YoYYoY
-1,077.97 %-934.20%
129.22 %-121.57%
-599.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

Year-over-Year Operating Cash Flow Growth of PRISM BioLab Co is -1,077.97 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Operating Cash Flow Growth PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

OCF growth measures the percentage change in operating cash flow. Growing OCF indicates improving cash generation from core operations.

To evaluate Year-over-Year Operating Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Operating Cash Flow Growth.

Year-over-Year Operating Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Operating Cash Flow Growth's PRISM BioLab Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co